Page last updated: 2024-12-07

oxymatrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxymatrine is a quinolizidine alkaloid isolated from the root of the medicinal herb Sophora flavescens. It has been shown to possess a wide range of pharmacological activities, including anti-inflammatory, antiviral, anticancer, and immunomodulatory effects. The compound has also been investigated for its potential therapeutic use in treating liver diseases, autoimmune diseases, and neurological disorders. Its complex structure and diverse biological activities make it a target of ongoing research efforts to understand its mechanisms of action and to develop new therapeutic applications.'

oxysophoridine: an alkaloid isolated from Sophra alope; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxymatrine: structure in first source; has anti-apoptosis effects [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114850
CHEMBL ID458337
CHEBI ID2672
SCHEMBL ID13394285
MeSH IDM0113607
PubMed CID24864132
MeSH IDM0113607

Synonyms (58)

Synonym
AC-6063
16837-52-8
ammothamnine
matrine n-oxide
MLS001215101
smr000543093
CHEMBL458337
chebi:2672 ,
(7as,13ar,13br,13cs)dodecahydro-1h,5h,10h-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one 4-oxide
STK801916
AKOS004120031
HMS2854E03
NCGC00346596-01
S2338
AKOS022168212
BBL030371
oxysophoridine
54809-74-4
SCHEMBL13394285
sophoridine n-oxide
MLS006011817
oxymatrine,(s)
Q-100202
XVPBINOPNYFXID-LHDUFFHYSA-N
mfcd00210339
pachycarpidine
NCGC00346596-02
rel-(41s,7as,13ar,13br)-10-oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide
1212383-03-3
(1r,2r,9s,13r,17s)-13-oxido-7-aza-13-azoniatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one
oxymatrine (matrine n-oxide)
DTXSID40937482
AS-15173
Q15425294
AMY25589
CCG-267091
(1r,2r,9s,17s)-13-oxido-7-aza-13-azoniatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one
A870349
1h,5h,10h-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one,dodecahydro-, 4-oxide, (7ar,13ar,13br,13cs)-
bdbm50597716
(1r,2r,9s,17s)-6-oxo-7,13-diazatetracyclo[7.7.1.0?,?.0??,??]heptadecan-13-ium-13-olate
rel-(41s,7as,13ar,13br)-10-oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine4-oxide
(+)-oxymatrine
matrine 1beta-oxide
1h,5h,10h-dipyrido(2,1-f:3',2',1'-ij)(1,6)naphthyridin-10-one, dodecahydro-, 4-oxide, (4r,7as,13ar,13br,13cs)-
matrine, 1-oxide
matridin-15-one, 1-oxide, (1-beta)-
matrine oxide
oxymatrine
hsdb 8102
85u4c366qs ,
unii-85u4c366qs
(7as,13ar,13br,13cs)-dodecahydro-1h,5h,10h-dipyrido(2,1-f:3',2',1'-ij)(1,6)naphthyridin-10-one 4-oxide
oxymatrine [who-dd]
(4r,7as,13ar,13br,13cs)-dodecahydro-1h,5h,10h-dipyrido(2,1-f:3',2',1'-ij)(1,6)naphthyridin-10-one 4-oxide
HY-N0158
CS-6157
Q63396010

Research Excerpts

Overview

Oxymatrine is a natural anti-hepatitis B virus (HBV) drug. It down-regulates host heat-stress cognate 70 (Hsc70) expression through a mechanism different from that of nucleosides.

ExcerptReferenceRelevance
"Oxymatrine (1) is a natural anti-hepatitis B virus (HBV) drug that down-regulates host heat-stress cognate 70 (Hsc70) expression through a mechanism different from that of nucleosides. "( Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators.
Du, NN; Gao, LM; Jiang, JD; Li, CX; Li, X; Liu, F; Liu, YX; Peng, ZG; Song, DQ; Wang, YP, 2011
)
1.81

Toxicity

ExcerptReferenceRelevance
"68 mg L(-1)), while chlorfluazuron was the least acutely toxic of the tested compounds (LC(50) = 2,526 mg L(-1))."( Toxic effect and biochemical study of chlorfluazuron, oxymatrine, and spinosad on honey bees (Apis mellifera).
Badawy, ME; Nasr, HM; Rabea, EI, 2010
)
0.36
" tonkinensis) held great value in the clinical application of traditional Chinese medicine, but cardiotoxic effects were reported, with matrine, oxymatrine, cytisine, and sophocarpine being the primary toxic components."( An integrated characterization of contractile, electrophysiological, and structural cardiotoxicity of Sophora tonkinensis Gapnep. in human pluripotent stem cell-derived cardiomyocytes.
Cheng, Q; Sun, G; Sun, X; Wang, M; Wang, R; Wang, S; Xie, X; Yang, K; Ye, J; Zhou, P, 2019
)
0.51

Pharmacokinetics

The aim of this research is to assess the biopharmaceutical and pharmacokinetic activities of oxymatrine and clarify its mechanisms of absorption and metabolism. The method herein described is successfully applied to the evaluation of Pharmacokinetic profiles of oxysophocarpine pills in 18 healthy volunteers.

ExcerptReferenceRelevance
" The methods were applied to a pharmacokinetic study of baicalin and oxymatrine in rabbits."( HPLC analyses and pharmacokinetic studies of baicalin and oxymatrine in rabbits.
He, ZG; Li, HZ; Qiu, F, 2003
)
0.32
" Pharmacokinetic data of OMT and its active metabolite MT obtained with this method following a single oral dose of 300 mg OMT capsules to six beagle dogs was also reported for the first time."( Simultaneous determination of oxymatrine and its active metabolite matrine in dog plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies.
Li, X; Ma, R; Sheng, L; Sun, J; Wang, G; Wang, S, 2005
)
0.33
" The method herein described is successfully applied to the evaluation of pharmacokinetic profiles of oxymatrine tablets pills in 18 healthy volunteers."( Determination of oxymatrine in human plasma by LC-MS and study on its pharmacokinetics.
Ma, PC; Xiang, BR; Zhang, W, 2008
)
0.35
"To establish an HPLC-MS method for simultaneous determination of matrine, oxymatrine and oxysophocarpine in rat plasma after oral administration of herbal preparation, namely Sanwu Huangqin decoction, and the pharmacokinetic porameters were calculated as well."( [Simultaneous determination of matrine, oxysophocarpin and oxymatrine in rat plasma by HPLC-MS and its application in the pharmacokinetic study].
Bi, KS; Chen, XH; Lian, JW; Wang, ZW; Zhang, L; Zhou, H, 2008
)
0.35
"The pharmacokinetic parameters of self-made sustained-release tablets versus those of its control preparation were as follows: Tmax: (6."( [Pharmacokinetics and bioavailability of sustained-release tablets of matrine in dogs].
Li, GF; Li, ZW; Zhang, JH, 2010
)
0.36
"The purpose of this study is to systematically investigate the pharmacokinetic (PK) behaviors of radix Sophorae tonkinensis (S."( Pharmacokinetic characterization of oxymatrine and matrine in rats after oral administration of radix Sophorae tonkinensis extract and oxymatrine by sensitive and robust UPLC-MS/MS method.
Dong, LN; Li, Y; Liu, ZQ; Peng, XJ; Shi, J; Tang, L; Zhou, FY, 2013
)
0.39
" This study aims to investigate the pharmacokinetic (PK) study of matrine (MT), oxymatrine (OMT), glycyrrhizic acid (GL) and glycyrrhetinic acid (GA) following oral administration of KGD in rats."( Pharmacokinetic study of multiple active constituents from Kushen-Gancao Decoction after oral administration in rat by HPLC-MS/MS.
Dang, X; Shi, L; Tang, X; Wang, Q; Zhang, Y, 2014
)
0.4
" Pharmacokinetic parameters were determined in rats following oral (p."( Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats.
Fan, S; Jin, X; Li, J; Liao, S; Shi, W; Wang, J; Wang, X; Zhang, T; Zhang, W; Zhang, Z; Zhong, B, 2016
)
0.43
"The aim of this research is to assess the biopharmaceutical and pharmacokinetic activities of oxymatrine and clarify its mechanisms of absorption and metabolism."( Biopharmaceutical and Pharmacokinetic Activities of Oxymatrine Determined by a Sensitive UHPLC-MS/MS Method.
Chen, FH; Chi, LQ; Wang, GH; Wang, HQ; Wang, L, 2022
)
0.72

Compound-Compound Interactions

IFN or oxymatrine in combination with ongoing lamivudine therapy provided effective antiviral therapy in patients with lamvudine-resistant HBV.

ExcerptReferenceRelevance
"73% patients treated with combination with IFN, and in 13."( [IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B].
Cheng, YQ; Fu, JL; Lan, Y; Li, HW; Lou, M; Zhao, P, 2004
)
0.32
"These data indicated that IFN or oxymatrine in combination with ongoing lamivudine therapy provided effective antiviral therapy in patients with lamivudine-resistant HBV."( [IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B].
Cheng, YQ; Fu, JL; Lan, Y; Li, HW; Lou, M; Zhao, P, 2004
)
0.32
"To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells."( [Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].
Sun, Q; Wang, L; Wang, XY; Xu, ZP; Zhang, YR; Zhou, Z; Zhu, JS; Zhu, L, 2010
)
0.36
"Methyl thiazolyl tetrazolium assay was used to examine the effects of OI combined with low-dose paclitaxel on proliferation of SGC-7901 cells."( [Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].
Sun, Q; Wang, L; Wang, XY; Xu, ZP; Zhang, YR; Zhou, Z; Zhu, JS; Zhu, L, 2010
)
0.36
"OI combined with low-dose paclitaxel can inhibit VEGF and CXCR4 of gastric carcinoma SGC-7901 cells markedly, which may be one of its mechanisms of anti-angiogenic ability."( [Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].
Sun, Q; Wang, L; Wang, XY; Xu, ZP; Zhang, YR; Zhou, Z; Zhu, JS; Zhu, L, 2010
)
0.36
" It is concluded that APG in combination with OMT could inhibit non-small lung cancer, and the mechanism may be related to EGFR and its downstream signaling pathways."( [Effect of apigenin in combination with oxymatrine on non-small cell lung cancer and mechanism].
Chen, L; Deng, XR; DU, HZ; Ji, RS; Li, ZY; Liu, DH; Lu, S; Wang, ZL; Wu, T, 2023
)
0.91

Bioavailability

Oxymatrine (OMT) exhibits antipruritic and anti-inflammatory effects in squaric acid dibutyl ester (SADBE) induced ACD mice model. Need for frequent administration stipulated by short half-life and low bioavailability limits clinical application.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"It is concluded that after oral administration of oxymatrine-phospholipid complex in rats the bioavailability of oxymatrine is increased greatly."( [Study on bioavilability of oxymatrine-phospholipid complex in rats].
Han, YM; Yan, D; Yuan, HL, 2007
)
0.34
" Relative bioavailability is 104."( Determination of oxymatrine in human plasma by LC-MS and study on its pharmacokinetics.
Ma, PC; Xiang, BR; Zhang, W, 2008
)
0.35
"The objective of this study was to prepare oxymatrine-phospholipid complex (OMT-PLC) to enhance oral bioavailability of oxymatrine."( Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex.
Li, XY; Yang, M; Yuan, HL; Yue, PF; Zhu, WF, 2010
)
0.36
"To study the pharmacokinetics and bioavailability of sustained-release tablets of Matrine in dogs."( [Pharmacokinetics and bioavailability of sustained-release tablets of matrine in dogs].
Li, GF; Li, ZW; Zhang, JH, 2010
)
0.36
"Oxymatrine (OMT), a water-soluble drug, has a very low oral bioavailability because of its low membrane permeability and its biotransformation in the gastrointestinal tract."( A combination of a microemulsion and a phospholipid complex for topical delivery of oxymatrine.
Cao, FH; Li, SP; OuYang, WQ; Wang, YP; Yue, PF, 2011
)
0.37
" Finally, we confirmed that oral OMT with sustained release led to a gradual sustained plasma profile of both OMT, with a reduction in its bioavailability, and MT with an increase in the bioavailability compared with that of oral OMT with immediate release."( Development of an osmotically-driven pellet coated with acrylic copolymers (Eudragit® RS 30 D) for the sustained release of oxymatrine, a freely water soluble drug used to treat stress ulcers (I): in vitro and in vivo evaluation in rabbits.
Cui, F; Li, X; Liu, S; Piao, H, 2013
)
0.39
"Oxymatrine (OM) can be metabolized to matrine in gastrointestinal ileocecal valve after oral administration, which affects pharmacological activity and reduce bioavailability of OM."( Development and evaluation of alginate-chitosan gastric floating beads loading with oxymatrine solid dispersion.
Chen, L; Hou, Y; Liu, Y; Wang, W; Yang, J; Zhou, C, 2016
)
0.43
" The 2 perfusion techniques indicated that poor bioavailability of OMT in rats is due mostly to poor absorption and higher hepatic elimination and CYP3A2 appears to contribute to OMT metabolism in rat liver."( The Disposition of Oxymatrine in the Vascularly Perfused Rat Intestine-Liver Preparation and Its Metabolism in Rat Liver Microsomes.
Cen, MF; Chen, JS; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zhong, YM, 2016
)
0.43
" Sodium citrate, SDS and deoxysodium cholate serve as excellent absorption enhancers which are useful for the related research improving the oral bioavailability of OMT."( Absorption mechanism of oxymatrine in cultured Madin-Darby canine kidney cell monolayers.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" Oxymatrine (OMT) exhibits antipruritic and anti-inflammatory effects in squaric acid dibutyl ester (SADBE) induced ACD mice model, but the need for frequent administration stipulated by short half-life and low bioavailability limits clinical application."( Analgesic and antipruritic effects of oxymatrine sustained-release microgel cream in a mouse model of inflammatory itch and pain.
Chen, F; Fan, Q; Liu, Y; Long, L; Nie, H; Verkhratsky, A; Wu, Y; Zeng, H; Zhang, X; Zhang, Z; Zhao, J; Zhou, D; Zhu, T, 2020
)
0.56
" This study aimed at delivering APG and improving bioavailability by a food-friendly co-amorphous formulation of APG with oxymatrine (OMT)."( Apigenin-oxymatrine binary co-amorphous mixture: Enhanced solubility, bioavailability, and anti-inflammatory effect.
Du, H; Feng, Y; Hu, Y; Jiang, C; Li, B; Lu, S; Wu, T, 2022
)
0.72
"Coamorphous drug delivery systems have shown great potential in improving the solubility and bioavailability of poorly water-soluble drugs."( Exploring the Formation Mechanism of Coamorphous Andrographolide-Oxymatrine Based on Molecular Dynamics and Spectroscopy.
Cao, Y; Fang, X; Han, L; Hu, Y; Huang, Z; Li, B; Lu, S, 2022
)
0.72
"Apigenin (APG) is a well-known dietary flavonoid with multiple bioactivities, but its poor aqueous solubility may result in low oral bioavailability and thus compromised therapeutic effects."( Complexation of Apigenin and Oxymatrine Leading to Enhanced Anti-inflammatory Activity.
Cao, J; Du, H; Guo, Y; Li, B; Li, X; Lu, S; Wang, X; Wang, Y; Wang, Z; Yuan, D, 2023
)
0.91

Dosage Studied

Oxymatrine below dosage of 1 g x L(-1) showed the little inhibition effect on the HepG2 cells proliferation and exhibited the significant inhibition effect from 1 to 8g x L (-1) in both a time-and dose-dependent manner.

ExcerptRelevanceReference
"Four groups (6 mice in each group) were injected intraperitoneally with oxy at the dosage of 100, 200, and 300 mg/kg or with saline once a day for 30 days."( Inhibition of hepatitis B virus by oxymatrine in vivo.
Cai, X; Chen, XS; Hu, YP; Wang, GJ; Yu, HY, 2001
)
0.31
"Oxymatrine can reduce the contents of HBsAg and HBcAg in transgenic mice liver,longer treatment time and larger dosage do not yield better effects."( Inhibition of hepatitis B virus by oxymatrine in vivo.
Cai, X; Chen, XS; Hu, YP; Wang, GJ; Yu, HY, 2001
)
0.31
" The rats in group A were injected muscularly with oxymatrine at the dosage of 63 mg/(kg."( Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats.
Liu, WZ; Lu, LG; Niu, FL; Shi, Y; Zheng, P, 2005
)
0.33
"The coating prescription is filtered by the release extent of matrine and oxymatrine in vitro and the wicking rate of the tablet, which including the category and proportion of film forming agent and porogen, the sort and dosage of fluidizing agent, the increment of weight after coating and so on."( [Preparation and in vivo evaluation of pH and time dependent Yuchangning tablets for colon-specific delivery].
Qiu, XL; Xie, XL; Xu, HY; Xu, RC; Yang, M, 2007
)
0.34
"To establish a suitable dosage form for a traditional anti-anaphylaxis Chinese medicine of Kushen recipe, and investigate the effect of cutaneous permeation in vitro of the recipe."( [Studies on cutaneous permeation in vitro of Kushen recipe gel].
Hu, JH; Liu, JY; Peng, C; Qin, Z; Wang, J; Zhu, QG, 2007
)
0.34
"It was certified that the purifying extraction gel had improved the effect of cutaneous permeation of alkaloids, and it is the befitting dosage form for Kushen recipe to treat anaphylaxis disease in skin."( [Studies on cutaneous permeation in vitro of Kushen recipe gel].
Hu, JH; Liu, JY; Peng, C; Qin, Z; Wang, J; Zhu, QG, 2007
)
0.34
" Experimental hepatic fibrosis was induced by subcutaneous injection of carbon tetrachloride (CCl4 soluted in liquid paraffin with the concentration of 300 g/L, the dosage of injection was 3 mL/kg, twice per week for 8 wk)."( Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.
Jiang, MD; Qin, JP; Wu, XL; Xu, H; Zeng, WZ, 2008
)
0.35
"Oxymatrine below dosage of 1 g x L(-1) showed the little inhibition effect on the HepG2 cells proliferation and exhibited the significant inhibition effect from 1 to 8 g x L(-1) in both a time-and dose-dependent manner."( [Effects of oxymatrine on proliferation of HepG2 cells].
Qin, X; Yin, J; Zhang, H, 2009
)
0.35
"Sixty-five CHB patients who had HBV DNA(3)10(4) copies/ml, positive HBeAg, positive human leukocyte antigen (HLA)-A2, alanine aminotransferase (ALT) > 2 x upper limit of normal value (ULN) were randomly divided into two groups: treatment group (n = 33), treated with an intravenous infusion of 600 mg oxymatrine in glucose solution once a day for a month, then with a 200 mg oxymatrine oral capsule three times a day, and a 200 mg silibin meglumine tablet three times a day; control group (n = 32) patients were treated only with silibin meglumine tablet, method and dosage were the same as those of treatment group."( Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B.
Chen, HK; Gu, XB; Hua, Z; Jiang, YM; Lu, ZH; Pei, H; Wu, HY; Yang, XJ; Zhang, B; Zhu, YF, 2012
)
0.38
" The rats in the treatment group received oxymatrine via celiac injection at a dosage of 40 mg/kg once a day at the same time."( Effect of oxymatrine on hepatic gene expression profile in experimental liver fibrosis of rats.
He, Y; Jian, YC; Jiang, M; Li, W; Liu, YB; Xiong, WJ, 2012
)
0.38
"To evaluate the analgesic and antipruritic effects of OMT gel (OG), OMT sustained release microgel powder (OMP) and OMT sustained release microgel cream (OMC) in SADBE induced ACD mice, with subsequent study of the mechanism and side effects (irritation) of optimal dosage form."( Analgesic and antipruritic effects of oxymatrine sustained-release microgel cream in a mouse model of inflammatory itch and pain.
Chen, F; Fan, Q; Liu, Y; Long, L; Nie, H; Verkhratsky, A; Wu, Y; Zeng, H; Zhang, X; Zhang, Z; Zhao, J; Zhou, D; Zhu, T, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
tertiary amine oxideAn N-oxide where there are three organic groups bonded to the nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.01191.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyruvate kinase PKMHomo sapiens (human)IC50 (µMol)5.00000.50002.788610.0000AID1881909
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (107)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1242264Immunoregulatory activity in BALC/c mouse assessed as reduction in NK cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID523466Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 113 uM after 72 hrs by RT-PCR analysis in presence of adefovir2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1387671Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 0.4 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus.
AID1242269Antiviral activity against human enterovirus 71 infected in ICR mouse assessed as increase in survival rate at 15 mg/kg, ip qd for 8 days dosed 2 hrs post infection and measured at 14 days post infection relative to control2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID523453Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 1.51 mM after 36 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523445Cytotoxicity against human HepG2(2.2.15) cells assessed as cell survival at 113 mM continuous exposure measured after 7 months2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523456Decrease in Luc mRNA expression in human sHepG2(2.2.15) cells expressing pLuc-5'UTR after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1242262Immunoregulatory activity in BALC/c mouse assessed as reduction in B cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID523467Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 113 uM after 72 hrs by RT-PCR analysis in presence of entecavir2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523471Therapeutic index, ratio of CC50 for human sHepG2(2.2.15) cells to IC50 for Hepatitis B virus2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID261704Cytotoxicity against HepG2 2.2.15 cell line at 0.4 umol/mL by MTT assay2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
(+)-12alpha-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens.
AID1234208Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect at maximal nontoxic concentration dosed 1 hr after viral adsorption2015Journal of natural products, Jul-24, Volume: 78, Issue:7
Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID570165Inhibition of Hsc70 mRNA expression in human HepG2(2.2.15) cells at 100 ug/ml after 24 hrs by RT-PCR analysis2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70.
AID523451Decrease in Hsc70-protein expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM after 24 hrs by flow-cytometric assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523468Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA level at 23.6 uM to 1.51 mM after 72 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523455Decrease in Luc mRNA expression in human sHepG2(2.2.15) cells expressing pLuc-3'UTR after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523454Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in supernatant viral DNA level at 1.51 mM after 36 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1242263Immunoregulatory activity in BALC/c mouse assessed as reduction in DC cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1234209Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect at maximal nontoxic concentration dosed 1 hr after viral adsorption2015Journal of natural products, Jul-24, Volume: 78, Issue:7
Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID1242259Immunoregulatory activity in BALC/c mouse assessed as increase in CD3+ T cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID523605Antiviral activity against adefovir-resistant Hepatitis B virus infected in human Huh-7 cells assessed as suppression of viral replication at 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523459Decrease in HscA90-mRNA expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523457Decrease in wild type Luc mRNA expression in human HepG2(2.2.15) cells after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523458Decrease in HscA4-mRNA expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID261700Inhibition of HBsAg release against HBV in HepG2 2.2.15 cell line at 0.2 umol/mL2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
(+)-12alpha-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens.
AID1881909Inhibition of PKM2 (unknown origin) Ala366, Hie78, Asn75, Lys207, Gly363 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID523608Antiviral activity against drug-resistant chronic Hepatitis B virus infected patients assessed as reduction in viral DNA at 0.4 g/day, po for 12 months2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523450Decrease in Hsc70-protein expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM after 24 hrs by Western blot analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523462Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 113 uM after 72 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523448Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth at 1.51 mM after 36 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523473Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in genomic viral DNA at 23.6 uM to 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1577758Inhibition of TGFbeta1 receptor in TGFbeta1-stimulated Sprague-Dawley rat cardiac fibroblasts assessed as reduction in alpha-SMA expression at 2 mM measured after 12 hrs by Western blot analysis
AID1577760Inhibition of TGFbeta1 receptor in TGFbeta1-stimulated Sprague-Dawley rat cardiac fibroblasts assessed as reduction in collagen 3 expression at 2 mM measured after 12 hrs by Western blot analysis
AID1387675Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 0.4 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus.
AID523607Half life in human blood2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523449Decrease in Hsc70- mRNA expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523603Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA level at 113 mM continuous exposure measured after 7 months by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1160745Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Identification and synthesis of quinolizidines with anti-influenza a virus activity.
AID523606Antiviral activity against entecavir-resistant Hepatitis B virus infected in human Huh-7 cells assessed as suppression of viral replication at 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523469Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA level by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523452Decrease in Hsc70- mRNA expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM after 72 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1577757Inhibition of TGFbeta1 receptor in TGFbeta1-stimulated Sprague-Dawley rat cardiac fibroblasts assessed as reduction in fibronectin expression at 2 mM measured after 12 hrs by Western blot analysis
AID523472Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replicative intermediates at 23.6 uM to 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523604Cytotoxicity against human HepG2(2.2.15) cells assessed as cell survival at 113 mM continuous exposure measured after 2 months2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID261701Inhibition of HBsAg release against HBV in HepG2 2.2.15 cell line at 0.1 umol/mL2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
(+)-12alpha-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens.
AID523447Decrease in Hsc70- mRNA expression in human liver HepG2 cells at 0.23 to 0.94 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523476Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA level at 113 mM continuous exposure measured after 2 months by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID261702Inhibition of HBeAg release against HBV in HepG2 2.2.15 cell line at 0.2 umol/mL2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
(+)-12alpha-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens.
AID613769Inhibition of Hsc70 mRNA expression in human HepG2(2.2.15) cells at 100 ug/ml after 24 hrs by RT-PCR analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators.
AID613770Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of intracellular HBV DNA replication at 100 ug/mL for 24 hrs by RT-PCR analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators.
AID1160744Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Identification and synthesis of quinolizidines with anti-influenza a virus activity.
AID523475Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral mRNA level at 1.51 mM for 12, 24 or 36 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1242260Immunoregulatory activity in BALC/c mouse assessed as increase in CD4+ T cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1387679Cytotoxicity against human HepG2.2.15 cells assessed as growth inhibition at 0.8 mM by MTT assay relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus.
AID1577759Inhibition of TGFbeta1 receptor in TGFbeta1-stimulated Sprague-Dawley rat cardiac fibroblasts assessed as reduction in collagen 1 expression at 2 mM measured after 12 hrs by Western blot analysis
AID1242261Immunoregulatory activity in BALC/c mouse assessed as increase in CD8+ T cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID261703Inhibition of HBeAg release against HBV in HepG2 2.2.15 cell line at 0.1 umol/mL2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
(+)-12alpha-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens.
AID523444Reduction in Hsc70 mRNA half-life in Hepatitis B virus infected in human HepG2(2.2.15) cells at 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523470Cytotoxicity against human HepG2(2.2.15) cells assessed as cell killing by MTT assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523446Antiviral activity against lamivudine-resistant Hepatitis B virus infected in human Huh-7 cells assessed as suppression of viral replication at 1.51 mM after 24 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID523474Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA level at 1.51 mM for 12, 24 or 36 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID613773Down regulation of Hsc70 protein level in human HepG2(2.2.15) cells after 24 hrs by RT-PCR analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (444)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (2.03)18.7374
1990's15 (3.38)18.2507
2000's96 (21.62)29.6817
2010's245 (55.18)24.3611
2020's79 (17.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.95 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index5.58 (4.65)
Search Engine Demand Index61.83 (26.88)
Search Engine Supply Index2.21 (0.95)

This Compound (40.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials16 (3.88%)5.53%
Reviews0 (0.00%)6.00%
Reviews18 (4.37%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
Other378 (91.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02202473]Phase 4192 participants (Actual)InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]